vs
agilon health, inc.（AGL）与英格索兰（IR）财务数据对比。点击上方公司名可切换其他公司
英格索兰的季度营收约是agilon health, inc.的1.3倍（$2.1B vs $1.6B），英格索兰净利率更高（12.7% vs -12.0%，领先24.8%），英格索兰同比增速更快（10.1% vs 3.1%），英格索兰自由现金流更多（$461.5M vs $-23.5M），过去两年英格索兰的营收复合增速更高（11.9% vs -1.1%）
agilon health是一家美国医疗保健企业，主要与基层医疗服务提供者合作，为联邦医疗保险覆盖的老年群体提供价值导向型医疗解决方案，为医生提供行政支持、临床工具及风险管理框架，在提升诊疗效果的同时降低医疗成本，业务覆盖美国20余个州。
英格索兰是一家美国跨国企业，主营流体生产及工业产品业务。公司于2020年2月由原英格索兰plc的工业业务板块分拆后与加德纳丹佛合并组建，旗下拥有40多个品牌，产品覆盖全球所有主要市场。
AGL vs IR — 直观对比
营收规模更大
IR
是对方的1.3倍
$1.6B
营收增速更快
IR
高出7.1%
3.1%
净利率更高
IR
高出24.8%
-12.0%
自由现金流更多
IR
多$485.0M
$-23.5M
两年增速更快
IR
近两年复合增速
-1.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.6B | $2.1B |
| 净利润 | $-188.9M | $266.1M |
| 毛利率 | — | 42.6% |
| 营业利润率 | -12.3% | 18.7% |
| 净利率 | -12.0% | 12.7% |
| 营收同比 | 3.1% | 10.1% |
| 净利润同比 | -78.5% | 15.8% |
| 每股收益（稀释后） | — | $0.67 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AGLIR
| Q4 25 | $1.6B | $2.1B | ||
| Q3 25 | $1.4B | $2.0B | ||
| Q2 25 | $1.4B | $1.9B | ||
| Q1 25 | $1.5B | $1.7B | ||
| Q4 24 | $1.5B | $1.9B | ||
| Q3 24 | $1.5B | $1.9B | ||
| Q2 24 | $1.5B | $1.8B | ||
| Q1 24 | $1.6B | $1.7B |
净利润AGLIR
| Q4 25 | $-188.9M | $266.1M | ||
| Q3 25 | $-110.2M | $244.1M | ||
| Q2 25 | $-104.4M | $-115.3M | ||
| Q1 25 | $12.1M | $186.5M | ||
| Q4 24 | $-105.8M | $229.8M | ||
| Q3 24 | $-117.6M | $221.6M | ||
| Q2 24 | $-30.7M | $185.0M | ||
| Q1 24 | $-6.1M | $202.2M |
毛利率AGLIR
| Q4 25 | — | 42.6% | ||
| Q3 25 | — | 43.7% | ||
| Q2 25 | — | 43.7% | ||
| Q1 25 | — | 44.6% | ||
| Q4 24 | — | 42.9% | ||
| Q3 24 | — | 43.8% | ||
| Q2 24 | — | 43.9% | ||
| Q1 24 | — | 44.7% |
营业利润率AGLIR
| Q4 25 | -12.3% | 18.7% | ||
| Q3 25 | -9.1% | 19.2% | ||
| Q2 25 | -8.3% | 4.0% | ||
| Q1 25 | -1.4% | 17.6% | ||
| Q4 24 | -7.1% | 20.0% | ||
| Q3 24 | -9.2% | 19.1% | ||
| Q2 24 | -2.9% | 15.1% | ||
| Q1 24 | -0.4% | 17.6% |
净利率AGLIR
| Q4 25 | -12.0% | 12.7% | ||
| Q3 25 | -7.7% | 12.5% | ||
| Q2 25 | -7.5% | -6.1% | ||
| Q1 25 | 0.8% | 10.9% | ||
| Q4 24 | -6.9% | 12.1% | ||
| Q3 24 | -8.1% | 11.9% | ||
| Q2 24 | -2.1% | 10.2% | ||
| Q1 24 | -0.4% | 12.1% |
每股收益（稀释后）AGLIR
| Q4 25 | — | $0.67 | ||
| Q3 25 | — | $0.61 | ||
| Q2 25 | — | $-0.29 | ||
| Q1 25 | — | $0.46 | ||
| Q4 24 | — | $0.57 | ||
| Q3 24 | — | $0.54 | ||
| Q2 24 | — | $0.45 | ||
| Q1 24 | — | $0.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $173.7M | $1.2B |
| 总债务越低越好 | $35.0M | $4.8B |
| 股东权益账面价值 | $126.7M | $10.1B |
| 总资产 | $1.3B | $18.3B |
| 负债/权益比越低杠杆越低 | 0.28× | 0.47× |
8季度趋势，按日历期对齐
现金及短期投资AGLIR
| Q4 25 | $173.7M | $1.2B | ||
| Q3 25 | $171.7M | $1.2B | ||
| Q2 25 | $171.4M | $1.3B | ||
| Q1 25 | $136.9M | $1.6B | ||
| Q4 24 | $188.2M | $1.5B | ||
| Q3 24 | $148.2M | $1.4B | ||
| Q2 24 | $109.5M | $1.1B | ||
| Q1 24 | $111.7M | $1.5B |
总债务AGLIR
| Q4 25 | $35.0M | $4.8B | ||
| Q3 25 | — | $4.8B | ||
| Q2 25 | — | $4.8B | ||
| Q1 25 | — | $4.8B | ||
| Q4 24 | — | $4.8B | ||
| Q3 24 | — | $4.8B | ||
| Q2 24 | — | $4.8B | ||
| Q1 24 | — | $2.7B |
股东权益AGLIR
| Q4 25 | $126.7M | $10.1B | ||
| Q3 25 | $306.1M | $10.1B | ||
| Q2 25 | $408.9M | $10.1B | ||
| Q1 25 | $500.3M | $10.5B | ||
| Q4 24 | $471.0M | $10.2B | ||
| Q3 24 | $574.9M | $10.3B | ||
| Q2 24 | $676.6M | $10.0B | ||
| Q1 24 | $689.3M | $9.9B |
总资产AGLIR
| Q4 25 | $1.3B | $18.3B | ||
| Q3 25 | $1.6B | $18.2B | ||
| Q2 25 | $1.7B | $18.1B | ||
| Q1 25 | $1.9B | $18.4B | ||
| Q4 24 | $1.7B | $18.0B | ||
| Q3 24 | $2.1B | $18.2B | ||
| Q2 24 | $2.2B | $17.8B | ||
| Q1 24 | $2.3B | $15.5B |
负债/权益比AGLIR
| Q4 25 | 0.28× | 0.47× | ||
| Q3 25 | — | 0.47× | ||
| Q2 25 | — | 0.47× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.47× | ||
| Q2 24 | — | 0.48× | ||
| Q1 24 | — | 0.27× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-20.5M | $499.0M |
| 自由现金流经营现金流 - 资本支出 | $-23.5M | $461.5M |
| 自由现金流率自由现金流/营收 | -1.5% | 22.1% |
| 资本支出强度资本支出/营收 | 0.2% | 1.8% |
| 现金转化率经营现金流/净利润 | — | 1.88× |
| 过去12个月自由现金流最近4个季度 | $-119.0M | $1.2B |
8季度趋势，按日历期对齐
经营现金流AGLIR
| Q4 25 | $-20.5M | $499.0M | ||
| Q3 25 | $-18.2M | $354.6M | ||
| Q2 25 | $-35.1M | $245.7M | ||
| Q1 25 | $-32.0M | $256.4M | ||
| Q4 24 | $16.4M | $526.2M | ||
| Q3 24 | $-7.7M | $404.0M | ||
| Q2 24 | $-18.7M | $304.9M | ||
| Q1 24 | $-47.8M | $161.6M |
自由现金流AGLIR
| Q4 25 | $-23.5M | $461.5M | ||
| Q3 25 | $-21.3M | $325.5M | ||
| Q2 25 | $-38.3M | $210.4M | ||
| Q1 25 | $-35.8M | $222.7M | ||
| Q4 24 | $13.2M | $490.9M | ||
| Q3 24 | $-11.2M | $374.3M | ||
| Q2 24 | $-22.0M | $283.1M | ||
| Q1 24 | $-50.9M | $99.3M |
自由现金流率AGLIR
| Q4 25 | -1.5% | 22.1% | ||
| Q3 25 | -1.5% | 16.6% | ||
| Q2 25 | -2.7% | 11.1% | ||
| Q1 25 | -2.3% | 13.0% | ||
| Q4 24 | 0.9% | 25.9% | ||
| Q3 24 | -0.8% | 20.1% | ||
| Q2 24 | -1.5% | 15.7% | ||
| Q1 24 | -3.2% | 5.9% |
资本支出强度AGLIR
| Q4 25 | 0.2% | 1.8% | ||
| Q3 25 | 0.2% | 1.5% | ||
| Q2 25 | 0.2% | 1.9% | ||
| Q1 25 | 0.3% | 2.0% | ||
| Q4 24 | 0.2% | 1.9% | ||
| Q3 24 | 0.2% | 1.6% | ||
| Q2 24 | 0.2% | 1.2% | ||
| Q1 24 | 0.2% | 3.7% |
现金转化率AGLIR
| Q4 25 | — | 1.88× | ||
| Q3 25 | — | 1.45× | ||
| Q2 25 | — | — | ||
| Q1 25 | -2.64× | 1.37× | ||
| Q4 24 | — | 2.29× | ||
| Q3 24 | — | 1.82× | ||
| Q2 24 | — | 1.65× | ||
| Q1 24 | — | 0.80× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AGL
| Medical Services | $1.6B | 100% |
| Other Operating | $2.5M | 0% |
IR
| Transferred At Point In Time | $1.5B | 71% |
| Transferred Over Time | $193.0M | 9% |
| Precision And Science Technologies Segment | $183.1M | 9% |
| Acquisitions In2024 | $175.6M | 8% |
| Acquisitions In2025 | $70.8M | 3% |
